


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. -67. (canceled).

68. (currently amended): A compound represented by the following formula (I-B):



wherein R¹, R², R³ and R⁴ each independently represents (1) C1-8 alkyl, (2) C2-8 alkenyl, (3) a halogen atom, (4) trihalomethyl, (5) Cycl, (6) -OR⁶, or (7) C1-8 alkyl substituted with -OR⁶ or Cycl;

R⁶ represents (1) a hydrogen atom, (2) C1-8 alkyl, (3) C2-8 alkenyl, (4) Cycl, (5) methyl substituted with 1 to 3 halogen, or (6) C1-8 alkyl substituted with Cycl;

Cycl represents a C3-10 monocyclic or bicyclic carbocyclic group;

G represents a bond,

K and M each independently represents (1) a bond, (2) C1-8 alkylene, or (3) C2-8 alkenylene;

L represents a bond or an oxygen atom;

Ring A represents a C3-10 monocyclic or bicyclic carbocyclic group;

Ring B represents a C3-10 monocyclic or bicyclic carbocyclic group or a ~~three- to ten-~~ ~~membered monocyclic or bicyclic heterocyclic group which contains 1 to 5 hetero atoms selected from an oxygen atom(s), a nitrogen atom(s) and a sulfur atom(s)~~ pyrrolidine, piperidine, piperazine, morpholine, pyridine, thiazole, imidazole, pyrrole, pyrazole, indol, thiophene or 1,3-dioxaindan ring;

Ring D represents a C3-10 monocyclic carbocyclic group or a ~~three- to ten-membered monocyclic heterocyclic group which contains 1 to 5 hetero atoms selected from an oxygen atom(s), a nitrogen atom(s) and a sulfur atom(s)~~ piperidine, pyrrole, pyrazole, pyridine, 1,3,4-oxadiazole, thiazole or imidazole ring;

Ring E represents a C3-7 monocyclic carbocyclic group;

p, q, r and s each independently represents 0 or an integer of from 1 to 3,

in which R¹'s are the same or different when p represents 2 or more; R²'s are the same or different when q represents 2 or more; R³'s are the same or different when r represents 2 or more; and R⁴'s are the same or different when s represents 2 or more, respectively;

t represents 0 or 1; and

R⁵ represents (1) a hydrogen atom or (2) C1-8 alkyl, or
a salt thereof.

69. (previously presented) A pharmaceutical composition comprising the compound according to claim 68 or a salt thereof and a pharmaceutically acceptable carrier.

70. (currently amended) The pharmaceutical composition according to claim 69, which is an LPA receptor antagonist, wherein the LPA receptor is an EDG-2 receptor.

71. - 80.(canceled).